Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab

被引：64
|
作者：
Cousin, S. [1 ,2 ]
Toulmonde, M. [1 ,2 ]
Kind, M. [3 ]
Cazeau, A. -L. [4 ]
Bechade, D. [2 ]
Coindre, J. -M. [5 ]
Italiano, A. [1 ,2 ]
机构：
[1] Inst Bergonie, Early Phase Trials Unit, Bordeaux, France
[2] Inst Bergonie, Dept Med, Bordeaux, France
[3] Inst Bergonie, Dept Radiol, Bordeaux, France
[4] Inst Bergonie, Dept Nucl Med, Bordeaux, France
[5] Inst Bergonie, Dept Pathol, Bordeaux, France
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷 / 06期
关键词：
METASTATIC MELANOMA; IPILIMUMAB; PATIENT;
D O I：
10.1093/annonc/mdw125
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1178 / 1179
页数：2
相关论文
共 50 条
  • [41] Pulmonary Sarcoidosis Associated With Anti-Pd-L1 Therapy
    Balestra, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [42] Intrapleural Injection of Anti-PD1 Antibody: A Novel Management of Malignant Pleural Effusion
    Li, Xinying
    Wu, Guannan
    Chen, Cen
    Zhao, Yuan
    Zhu, Suhua
    Song, Xincui
    Yin, Jie
    Lv, Tangfeng
    Song, Yong
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [43] THE COMBINATION THERAPY OF ANTI-PD1 ANTIBODY PEMBROLIZUMAB AND ANTI-HER2 ANTIBODY TRASTUZUMAB EXERTS CARDIOTOXIC, PRO-INFLAMMATORY AND PRO-FIBROTIC PROPERTIES IN PRECLINICAL MODELS
    Maurea, Nicola
    Quagliariello, Vincenzo
    Caronna, Antonietta
    Rea, Domenica
    Barbieri, Antonio
    Monti, Maria Gaia
    Iaffaioli, Rosario Vincenzo
    De Laurentiis, Michelino
    Ascierto, Paolo
    Botti, Gerardo
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 1191 - 1191
  • [44] Development and validation of a UPLC-MS/MS method to quantitate anti-PD1 monoclonal antibody (Toripalimab), and comparison with electrochemiluminescence immunoassay
    Liu, Shuxia
    Yang, Jianliang
    Yang, Sheng
    Tan, Qiaoyun
    Dai, Liyuan
    Fan, Guangyu
    Wu, Di
    Zhang, Zhishang
    Yao, Jiarui
    Shi, Yuankai
    Han, Xiaohong
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2022, 209
  • [45] VEDOLIZUMAB PLUS ANTI-PD1 ANTIBODY IN ADVANCED MELANOMA PATIENTS WITH INFLAMMATORY ENTEROCOLITIS
    Javed, Asad
    Freesmeier, Michele
    Zakharia, Yousef
    Milhem, Mohammed
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1313 - A1313
  • [46] Pembrolizumab: a novel antiprogrammed death 1 (PD-1) monoclonal antibody for treatment of metastatic melanoma
    Tan, M.
    Quintal, L.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2015, 40 (05) : 504 - 507
  • [47] Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma
    Simeone, Ester
    Grimaldi, Antonio M.
    Ascierto, Paolo A.
    MELANOMA MANAGEMENT, 2015, 2 (01) : 41 - 50
  • [48] Anti-CTLA4 Monoclonal Antibody Induced Sarcoidosis in a Metastatic Melanoma Patient
    Eckert, A.
    Schoeffler, A.
    Dalle, S.
    Phan, A.
    Kiakouama, L.
    Thomas, L.
    DERMATOLOGY, 2009, 218 (01) : 69 - 70
  • [49] Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
    Shimizu, Toshio
    Seto, Takashi
    Hirai, Fumihiko
    Takenoyama, Mitsuhiro
    Nosaki, Kaname
    Tsurutani, Junji
    Kaneda, Hiroyasu
    Iwasa, Tsutomu
    Kawakami, Hisato
    Noguchi, Kazuo
    Shimamoto, Takashi
    Nakagawa, Kazuhiko
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (03) : 347 - 354
  • [50] Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
    Toshio Shimizu
    Takashi Seto
    Fumihiko Hirai
    Mitsuhiro Takenoyama
    Kaname Nosaki
    Junji Tsurutani
    Hiroyasu Kaneda
    Tsutomu Iwasa
    Hisato Kawakami
    Kazuo Noguchi
    Takashi Shimamoto
    Kazuhiko Nakagawa
    Investigational New Drugs, 2016, 34 : 347 - 354
12345